The effect of incorporation of cloxacillin in liposomes on treatment of experimental staphylococcal mastitis in mice

Journal of Veterinary Pharmacology and Therapeutics
J C Anderson, C J Kirby

Abstract

The effect of incorporation of cloxacillin in liposomes on the treatment of staphylococcal mastitis was assessed bacteriologically 18 h after treatment of experimental infections in mice caused by two strains of Staphylococcus aureus. Intramammary treatments were cloxacillin incorporated in liposomes, cloxacillin in combination with liposomes, empty liposomes, cloxacillin in saline and saline alone. In none of the experiments did entrapment of cloxacillin within liposomes enhance its antibacterial effects. Electron microscopic studies demonstrated the presence of liposomes in neutrophils which also contained staphylococci. The results support the hypothesis that intracellular staphylococci are metabolically dormant and therefore not susceptible to the action of inhibitors of cell wall synthesis such as cloxacillin.

References

Jun 1, 1978·Antimicrobial Agents and Chemotherapy·P F Bonventre, G Gregoriandis
Feb 3, 1977·Nature·G Gregoriadis
Sep 1, 1983·The Journal of Infectious Diseases·J V Desiderio, S G Campbell
Jul 1, 1982·Proceedings of the Society for Experimental Biology and Medicine·D M ReinitzI H Mather
Nov 1, 1938·The Journal of Hygiene·A A MilesJ O Irwin

❮ Previous
Next ❯

Citations

Apr 12, 2006·The Veterinary Quarterly·S Notebaert, E Meyer
Jul 1, 1989·The British Veterinary Journal·P G Francis
Jun 1, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shuyu XieZonghui Yuan
Sep 11, 2019·Materials Science & Engineering. C, Materials for Biological Applications·Raquel Silva AraújoVanessa Carla Furtado Mosqueira

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.